Vaxcyte Inc (PCVX) concluded trading on Thursday at a closing price of $35.24, with 3.85 million shares of worth about $135.5 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -68.76% during that period and on May 01, 2025 the price saw a loss of about -1.67%. Currently the company’s common shares owned by public are about 129.00M shares, out of which, 125.27M shares are available for trading.
Stock saw a price change of 2.12% in past 5 days and over the past one month there was a price change of 9.34%. Year-to-date (YTD), PCVX shares are showing a performance of -56.95% which decreased to -42.26% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $27.66 but also hit the highest price of $121.06 during that period. The average intraday trading volume for Vaxcyte Inc shares is 2.01 million. The stock is currently trading 10.48% above its 20-day simple moving average (SMA20), while that difference is down -35.74% for SMA50 and it goes to -58.12% lower than SMA200.
Vaxcyte Inc (NASDAQ: PCVX) currently have 129.00M outstanding shares and institutions hold larger chunk of about 107.96% of that.
The stock has a current market capitalization of $4.55B and its 3Y-monthly beta is at 1.27. It has posted earnings per share of -$3.88 in the same period. It has Quick Ratio of 12.75 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PCVX, volatility over the week remained 8.15% while standing at 9.32% over the month.
Analysts are in expectations that Vaxcyte Inc (PCVX) stock would likely to be making an EPS of -0.98 in the current quarter, while forecast for next quarter EPS is -1.04 and it is -4.85 for next year. For the current quarter EPS, analysts have given the company a lowest target -1.14 which is -0.81 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.85 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -20.61% while it is estimated to decrease by -3.20% in next year. EPS is likely to grow at an annualized rate of -6.42% for next 5-years, compared to annual growth of -29.88% made by the stock over the past 5-years.
Coverage by Goldman stated Vaxcyte Inc (PCVX) stock as a Buy in their note to investors on December 20, 2024, suggesting a price target of $135 for the stock. Stock get a Buy rating from Needham on January 03, 2023.
